Get the Stockscreener App
12.60
0.94%
-0.12
Pre-market:
13.10
0.50
+3.97%
Bicara Therapeutics Inc Stock (BCAX) Latest News
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat
Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) - Seeking Alpha
H.C. Wainwright lifts Bicara stock target to $45, maintains buy - MSN
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowTime to Sell? - MarketBeat
Bicara Therapeutics price target raised to $45 from $42 at H.C. Wainwright - MSN
Stifel maintains Buy on Bicara stock with $47 target By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 at HC Wainwright - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up After Analyst Upgrade - Defense World
Bicara reports positive Phase 1/1b trial results for cancer therapy By Investing.com - Investing.com South Africa
Bicara reports positive Phase 1/1b trial results for cancer therapy - Investing.com Nigeria
Bicara Therapeutics Presents Phase 1/1b Dose Expansion - GlobeNewswire
Stifel maintains Buy on Bicara stock with $47 target - Investing.com India
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up on Analyst Upgrade - MarketBeat
H.C. Wainwright lifts Bicara stock target to $45, maintains buy By Investing.com - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 - MarketBeat
Cantor Fitzgerald Weighs in on BCAX FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on BCAX FY2025 Earnings - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Average Price Target from Analysts - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Barclays PLC Purchases Shares of 10,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Initiates Corporate Presentation on Promising Corporate Strategy - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 4.1%Here's What Happened - MarketBeat
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Geode Capital Management LLC Buys Shares of 48,639 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Geode Capital Management LLC Takes $1.24 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Jane Street Group LLC Makes New $309,000 Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing - Reuters
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year LowWhat's Next? - MarketBeat
Barclays PLC Takes $255,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 2.9%What's Next? - MarketBeat
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
Most important biotech stories of 2024: IPOs, M&A deals and more layoffs - The Business Journals
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):